// App-Quantinova.ai

16993 : An Antisense Inhibitor of Apolipoprotein C-III Significantly Decreases Nonesterified Fatty Acid Levels in Severe Hypertriglyceridemic Patients

Researchers

Presenter

  • Diane Brisson

Principal Investigators

  • JoAnn Flaim

  • Steve Hughes

  • Walter Singleton

  • Richard Geary

  • Daniel Gaudet

Medical Centers

  • Dept of Med Univ de Montreal and ECOGENE, Chicoutimi, QC, Canada

Locations

  • Canada

Companies

  • Isis Pharmaceuticals

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Dyslipidemia

  • Type 2 diabetes mellitus

  • Diabetes

Biomarkers

  • N/A

Drug/Treatment

  • ISIS-APOCIIIRx

Outcome

  • N/A

Study Design

  • double blind/blinded

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved